osimertinib
astrazeneca
['adaura', 'lcsm,(-blcsm)', 'osimertinib', 'aura ,(-laura)']
important update of the adaura trial, confirming the dfs benefit from adjuvant osimertinib. 36-mo cns recurrence rates 2% vs. 13%! #lcsm #egfr #esmo2022 
Medical Oncologist at A.O. Papardo, Messina (Italy)